KURA ONCOLOGY, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
KURA ONCOLOGY, INC. (KURA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$278.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$278.37M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$171.97M.
- KURA ONCOLOGY, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$152.63M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$278.37M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$171.97M 10-K · filed 2026-03-05 |
| 2023-12-31 | -$152.63M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |